# Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide

Study · id `cardio:ct-nct06657209` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06657209](<https://clinicaltrials.gov/study/NCT06657209>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06657209

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 104 participants.

## Technical summary

Registry record NCT06657209. Randomized; no masking; primary purpose treatment. Start 2025-01-13 (actual); primary completion 2027-12-15 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 104 participants (planned count; ClinicalTrials.gov record NCT06657209, source copy `cardio:ctgov-nct06657209-2026-04-20`, retrieved 2026-10-26)
- Started: 2025-01-13 (actual) (ClinicalTrials.gov record NCT06657209, source copy `cardio:ctgov-nct06657209-2026-04-20`, retrieved 2026-10-26)
- Primary completion: 2027-12-15 (anticipated) (ClinicalTrials.gov record NCT06657209, source copy `cardio:ctgov-nct06657209-2026-04-20`, retrieved 2026-10-26)
- Completion: 2027-12-15 (anticipated) (ClinicalTrials.gov record NCT06657209, source copy `cardio:ctgov-nct06657209-2026-04-20`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT06657209, source copy `cardio:ctgov-nct06657209-2026-04-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06657209-2026-04-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide
- Condition: Diabetes Mellitus, Type 2
- Condition: Diabetes
- Condition: Type 2 Diabetes
- Condition: Pre Diabetes
- Intervention (Procedure): Insulin resistance testing
- Intervention (Procedure): OGTT
- Intervention (Procedure): Fat biopsy
- Intervention (Radiation): DXA scan
- Intervention (Procedure): MRI
- Intervention (Procedure): 1H-MRS
- Intervention (Drug): Tirzepatide
- Intervention (Drug): Pioglitazone
- Lead sponsor: Stanford University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Tirzepatide (`cardio:tirzepatide`)
- Registry lists this organization as the lead sponsor: Stanford University (`cardio:org-stanford-university`)

## Provenance

Content hash: bd8981757c800adbeecaa17cec9e523056fc27bed3fee75e874fd28b0a541440
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
